Patients with AEs of special interest related to atezolizumab (N = 42)
| . | Induction phase, n (%) . | Consolidation and follow-up phase, n (%) . |
|---|---|---|
| Any AESI | 4 (9.5) | 13 (31.0) |
| Increased lipase | 1 (2.4) | 3 (7.1) |
| Increased amylase | — | 3 (7.1) |
| Hypothyroidism | 1 (2.4) | 2 (4.8) |
| Pancreatitis | — | 2 (4.8) |
| Increased transaminases | 1 (2.4) | — |
| Infusion-related reaction | 1 (2.4) | — |
| Immune-mediated enterocolitis | — | 1 (2.4) |
| Eczema | — | 1 (2.4) |
| Rash | — | 1 (2.4) |
| Autoimmune hemolytic anemia | — | 1 (2.4) |
| Increased blood bilirubin | — | 1 (2.4) |
| Hepatitis | — | 1 (2.4) |
| Hyperbilirubinemia | — | 1 (2.4) |
| Basal cell carcinoma | — | 1 (2.4) |
| Malignant melanoma | — | 1 (2.4) |
| . | Induction phase, n (%) . | Consolidation and follow-up phase, n (%) . |
|---|---|---|
| Any AESI | 4 (9.5) | 13 (31.0) |
| Increased lipase | 1 (2.4) | 3 (7.1) |
| Increased amylase | — | 3 (7.1) |
| Hypothyroidism | 1 (2.4) | 2 (4.8) |
| Pancreatitis | — | 2 (4.8) |
| Increased transaminases | 1 (2.4) | — |
| Infusion-related reaction | 1 (2.4) | — |
| Immune-mediated enterocolitis | — | 1 (2.4) |
| Eczema | — | 1 (2.4) |
| Rash | — | 1 (2.4) |
| Autoimmune hemolytic anemia | — | 1 (2.4) |
| Increased blood bilirubin | — | 1 (2.4) |
| Hepatitis | — | 1 (2.4) |
| Hyperbilirubinemia | — | 1 (2.4) |
| Basal cell carcinoma | — | 1 (2.4) |
| Malignant melanoma | — | 1 (2.4) |